Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 457 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Epilepsy; Seizure Clear all

Conditions: Autistic Disorder, Seizures, Irritability
Interventions: N-Acetyl Cysteine (NAC); Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 6 Years to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Epileptic Encephalopathy, SCN2A Encephalopathy
Interventions: 1mg elsunersen, 0.5mg elsunersen; Drug
Lead sponsor: Praxis Precision Medicines; Industry
Eligibility: 1 Day to 18 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 6
States / cities: San Diego, California • Aurora, Colorado • Chicago, Illinois + 3 more

Conditions: Epilepsy, Seizures, Lennox-Gastaut Syndrome
Interventions: Ketogenic diet; Behavioral
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 1 Year to 10 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Epilepsy
Interventions: Levetiracetam; Drug
Lead sponsor: Drexel University College of Medicine; Other
Eligibility: 60 Years to 90 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Epilepsy
Interventions: Lacosamide; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 1 Month to 18 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 6
States / cities: Los Angeles, California • Orlando, Florida • Henderson, Nevada + 3 more

Conditions: Seizures
Interventions: Cannabidiol Oral Solution; Drug
Lead sponsor: INSYS Therapeutics Inc; Industry
Eligibility: 1 Year to 18 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 11
States / cities: San Francisco, California • Miami, Florida • Pensacola, Florida + 8 more

Conditions: Epilepsy, Lennox-Gastaut Syndrome
Interventions: GWP42003-P 20 mg/kg/day Dose, Placebo; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 2 Years to 55 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 17
States / cities: Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 14 more

Conditions: Epilepsy, Partial
Interventions: lamotrigine, 300 mg/day, lamotrigine, 250 mg/day; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 13 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 67
States / cities: Alabaster, Alabama • Litchfield Park, Arizona • Mesa, Arizona + 56 more

Conditions: Partial Epilepsy
Interventions: 800 mg QD Eslicarbazepine acetate, 1200 mg QD Eslicarbazepine acetate, Placebo; Drug
Lead sponsor: Bial - Portela C S.A.; Industry
Eligibility: 16 Years and older
Enrollment: 653 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 106
States / cities: Mobile, Alabama • Northport, Alabama • Phoenix, Arizona + 82 more

Conditions: Epilepsy
Interventions: Lacosamide; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 14
States / cities: Sacramento, California • Washington D.C., District of Columbia • Tampa, Florida + 11 more

Conditions: Epilepsy
Interventions: Carvedilol-CR; Drug
Lead sponsor: Columbia University; Other
Eligibility: 10 Years to 75 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Focal Epilepsy
Interventions: 40 mg/day vormatrogine for 12 weeks, 30 mg/day vormatrogine for 12 weeks, 20 mg/day vormatrogine for 12 weeks, Placebo; Drug
Lead sponsor: Praxis Precision Medicines; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 7
States / cities: Miami, Florida • Miami Lakes, Florida • Naples, Florida + 4 more

Conditions: Epilepsy
Interventions: Not listed
Lead sponsor: Cognizance Biomarkers, LLC; Industry
Eligibility: 12 Years and older
Enrollment: 371 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Neonatal Seizure, Hypoxic-Ischemic Encephalopathy, Stroke, Intracranial Hemorrhages, Epilepsy, Cerebral Palsy, Intellectual Disability
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 2 Years to 8 Years
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 9
States / cities: San Francisco, California • Stanford, California • Washington D.C., District of Columbia + 5 more

Conditions: Seizures
Interventions: levetiracetam; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 1 Day to 30 Days
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Epilepsy
Interventions: USL261; Drug
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 12 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 31
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 28 more

Conditions: Epilepsy, Seizure, Catamenial Epilepsy, Medically Resistant Epilepsy, Medically Resistant Seizures
Interventions: betaquik®; Dietary Supplement
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 2
States / cities: Baltimore, Maryland • Madison, Wisconsin

Conditions: Developmental and Epileptic Encephalopathy
Interventions: LP352; Drug
Lead sponsor: Longboard Pharmaceuticals; Industry
Eligibility: 2 Years to 66 Years
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 21
States / cities: Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 17 more

Conditions: Drug-Resistant Epilepsy, Focal-Onset Seizures
Interventions: Padsevonil; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 25
States / cities: Chandler, Arizona • La Jolla, California • San Francisco, California + 21 more

Conditions: Partial Epilepsy
Interventions: YKP3089; Drug
Lead sponsor: SK Life Science, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1,345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 39
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 32 more

Conditions: Absence Seizures, Absence Epilepsy
Interventions: Epihunter; Device
Lead sponsor: Epihunter NV; Industry
Eligibility: 4 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Epilepsy
Interventions: UPLIFT (Using Practice and Learning to Increase Favorable Thoughts), BOOST (Bringing Out Our Strength Together); Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 99 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Epilepsy, Monotherapy
Interventions: Lacosamide, Carbamazepine-Controlled Release; Drug
Lead sponsor: UCB BIOSCIENCES GmbH; Industry
Eligibility: 16 Years and older
Enrollment: 888 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 15
States / cities: Alabaster, Alabama • Huntsville, Alabama • Phoenix, Arizona + 12 more

Conditions: Epilepsy, Status Epilepticus, Seizures
Interventions: Not listed
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older
Enrollment: 20,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Search by objective public record fields.

Treatment Resistant Epilepsy and N-Acetyl Cysteine

A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety

Ketogenic Diet for Child Epilepsy and Seizure Control

Levetiracetam: The Anti-Convulsant of Choice for Elderly Patients With Dementia

A Study to Investigate the Safety and Efficacy of Lacosamide Added to the Patients Current Therapy in Patients Aged 1 Month to Less Than 18 Years Old With Epilepsy Syndromes Associated With Generalized Seizures.

Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder

A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults

Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures

A Multicenter, Open-Label Study To Investigate The Safety And Pharmacokinetics Of Lacosamide In Children With Partial Seizures

P-glycoprotein Inhibition as Adjunct Treatment for Medically Refractory Epilepsy.

Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures

Proof of Principle for a Diagnostic Blood Test of Recurrent Seizures

Neonatal Seizure Registry - Developmental Functional EValuation

Dosing of Levetiracetam (Keppra) in Neonates

Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters

Medium Chain Triglycerides as an Adjunct to the Modified Atkins Diet for Women With Catamenial Epilepsy

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)

Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy

Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

ECV - Epihunter Clinical Validation

Telephone-Based Support Programs for People With Epilepsy

Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older

De-identified UNMH EEG Corpus Database Creation With Fully De-identified Clinical Information